ARH-77 (ATCC® CRL-1621)

Organism: Homo sapiens, human  /  Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transformed  /  Tissue: peripheral blood  /  Disease: plasma cell leukemia

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue peripheral blood
Cell Type B lymphoblast; Epstein-Barr virus (EBV) transformed
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2 [Herpesvirus; cells contain EBV]

Biosafety  classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease plasma cell leukemia
Age 33 years
Gender female
Ethnicity Caucasian
Storage Conditions liquid nitrogen vapor phase
Images CRL-1621 Micrograph
Derivation
The ARH-77 cell line was established from the peripheral blood of a patient suffering from IgG plasma cell leukemia.

Although established from cells taken from a patient with a plasma cell leukemia, this line has been shown to be an EBV-transformed B lymphoblastoid cell line.

Clinical Data 33 years
female
Caucasian
Antigen Expression
CD11a +; CD19 +; CD20 +; CD28 +; CD38 -; CD49e +
Comments

The cells are positive for Epstein-Barr nuclear antigen(EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +).

The line has been cured of a previous mycoplasma infection.

LICR-LON-HMy2 (HMy2), a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), was irradiated and selected for class I loss to establish the HMy2.C1R (ATCC CRL-1993) cell line. Subsequently, C1R-neo (ATCC CRL-2369), C1R-sB7 (ATCC CRL-2370), and C1R-B7 (ATCC CRL-2371) were established by transfection of the HMy2.C1R cell line.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing

Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 x 105 viable cells/mL and maintain between 1 x 105 and 1 x 106 cells/mL.


Cryopreservation
Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C
STR Profile
D5S818: 10,13
D13S317: 11,13
D7S820: 7,12
D16S539: 9,13
vWA: 17
THO1: 8,9.3
Amelogenin: X
TPOX: 8
CSF1PO: 6,10
Isotype IgG1; kappa light chain
Name of Depositor BD Drewinko
References

Burk KH, et al. Establishment of a human plasma cell line in vitro. Cancer Res. 38: 2508-2513, 1978. PubMed: 566614

Cote RJ, et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA 80: 2026-2030, 1983. PubMed: 6572959

Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569

Edwards PA, et al. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur. J. Immunol. 12: 641-648, 1982. PubMed: 7140810

Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375

Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762

Drewinko B, et al. ARH-77, an established human IgG-producing myeloma cell line. I. Morphology, B-cell phenotypic marker profile, and expression of Epstein-Barr virus. Cancer 54: 1883-1892, 1984. PubMed: 6090003

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
References

Burk KH, et al. Establishment of a human plasma cell line in vitro. Cancer Res. 38: 2508-2513, 1978. PubMed: 566614

Cote RJ, et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA 80: 2026-2030, 1983. PubMed: 6572959

Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569

Edwards PA, et al. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur. J. Immunol. 12: 641-648, 1982. PubMed: 7140810

Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375

Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762

Drewinko B, et al. ARH-77, an established human IgG-producing myeloma cell line. I. Morphology, B-cell phenotypic marker profile, and expression of Epstein-Barr virus. Cancer 54: 1883-1892, 1984. PubMed: 6090003